Stay updated on MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The trial record now indicates Terminated status and a new Phase 1 SOS1 inhibitor study of MRTX0902 with 64 participants, including Phase 1 dose escalation and expansion cohorts, replacing prior Phase 1/2 entries.
    Difference
    2%
    Check dated 2026-02-25T06:51:15.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Removed the government funding lapse notice and Revision: v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-11T02:12:50.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The page now includes a government funding status notice about NIH operations. The site version has been updated to v3.4.1, replacing v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T00:44:48.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The page now includes a glossary toggle and updated QC metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted) along with the site revision (Revision: v3.4.0). The older labels/data references (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4) were removed.
    Difference
    0.2%
    Check dated 2026-01-28T00:20:52.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    Revision history updated to include v3.3.4 and remove v3.3.3.
    Difference
    0.0%
    Check dated 2026-01-14T00:33:58.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    Added a consolidated Locations section listing study sites by state (CT, DE, FL, MD, MN, NJ, OH, OR, PA, TN, TX, VA, WA) and removed individual state location subsections and the HHS Vulnerability Disclosure link; updated the revision from v3.3.2 to v3.3.3.
    Difference
    1%
    Check dated 2025-12-23T08:38:40.000Z thumbnail image

Stay in the know with updates to MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page.